Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | short review

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

verfasst von: Robert Zeiser, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.
Vorheriger Artikel Immunotherapy for nonsmall-cell lung cancer
Nächster Artikel Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders
Literatur
1.
2.
Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;5:389–96.CrossRef
3.
Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.CrossRefPubMed
4.
Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003;62:87–94.CrossRefPubMed
5.
Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.PubMed
6.
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRefPubMed
7.
Silvestris N, Leone B, Numico G, et al. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005;69:273–82.CrossRefPubMed
8.
McArdle PA, Canna K, McMillan DC, et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541–3.CrossRefPubMed
9.
Elkord E, Rowbottom AW, Kynaston H, et al. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin Immunol. 2006;120:91–8.CrossRefPubMed
10.
Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173:6098–108.PubMed
11.
Miller AM, Lundberg K, Ozenci V, et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398–405.PubMed
12.
Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.CrossRefPubMed
13.
Zheng X, Gao JX, Zhang H, et al. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol. 2002;169:4761–9.PubMed
14.
Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res. 2005;65:2947–55.CrossRefPubMed
15.
Dürr C, Pfeifer D, Claus R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70:10170–81.CrossRefPubMed
16.
Schellhammer PE, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol. 2003;23:47–9.CrossRef
17.
Michiels A, Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 2005;12:772–82.CrossRefPubMed
18.
Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 2005;12:699–707.CrossRefPubMed
19.
Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigen peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998;114:166–72.CrossRefPubMed
20.
Alexander RB, Brady F, Leffell MS. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology. 1998;51:150–7.CrossRefPubMed
21.
Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic Tlymphocytes specific for peptides derived from prostata-specific antigen. JNCI. 1997;89:293–300.CrossRefPubMed
22.
Thomas-Kaskel AK, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006;119:2428–34.CrossRefPubMed
23.
Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012;8:1–8.CrossRef
24.
Sims RB. Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J Cancer. 2011;2:357–9.CrossRefPubMed
25.
Tang S, Moore ML, Grayson JM, et al. Increased CD8+ T cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res. 2012;72:1975–85.CrossRefPubMed
26.
Akins EJ, Moore ML, Tang S, et al. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res. 2010;70:3473–82.CrossRefPubMed
27.
Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol. 2011;186:5162–72.CrossRefPubMed
28.
Radojevic K, Arsenovic-Ranin N, Kosec D, et al. Neonatal castration affects in trathymic kinetics of T cell differentiation and the spleen T-cell level. J Endocrinol. 2007;192:669–82.CrossRefPubMed
29.
Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009;69:571–84.CrossRefPubMed
30.
Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate. 2010;70:1002–11.PubMed
31.
Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–49.CrossRefPubMed
32.
Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430–9.CrossRefPubMed
33.
van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–17.CrossRefPubMed
34.
Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501–8.CrossRefPubMed
35.
Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849–59.CrossRefPubMed
36.
Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380–6.PubMed
37.
Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.CrossRefPubMed
38.
Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010;16:5269–76.CrossRefPubMed
Metadaten
Titel
Immunotherapeutic approaches targeting prostate cancer and its microenvironment
verfasst von
Robert Zeiser, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0021-4

Weitere Artikel der Ausgabe 2/2012

Evolving strategies to overcome endocrine resistance in breast cancer

  • review

Breast cancer: is there a need for biopsy of metastases?

  • short review

Recent advances and future challenges in the treatment of upper gastrointestinal malignancies

  • short review

Highlights in the adjuvant treatment of colon cancer from annual meetings 2011

  • short review

Immunotherapy for nonsmall-cell lung cancer

  • short review

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

  • short review